| Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy CD Miller, R El‐Kholi, JJ Faragon, TP Lodise Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27 (10 …, 2007 | 116 | 2007 |
| Progressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin CD Miller, BW Lomaestro, S Park, DS Perlin Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 26 (6 …, 2006 | 116 | 2006 |
| Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents J Adams, N Patel, N Mankaryous, M Tadros, CD Miller Annals of Pharmacotherapy 44 (1), 157-165, 2010 | 92 | 2010 |
| Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia TP Lodise, CD Miller, J Graves, A Evans, E Graffunder, M Helmecke, ... Journal of antimicrobial chemotherapy 62 (5), 1138-1141, 2008 | 85 | 2008 |
| Clinical Prediction Tool To Identify Patients with Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk for Multidrug Resistance TP Lodise, CD Miller, J Graves, JP Furuno, JC McGregor, B Lomaestro, ... Antimicrobial agents and chemotherapy 51 (2), 417-422, 2007 | 81 | 2007 |
| Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol GW Roberts, T Druskeit, LE Jorgensen, LMH Wing, AS Gallus, C Miller, ... Australian and New Zealand journal of medicine 29 (5), 731-736, 1999 | 77 | 1999 |
| Are vancomycin trough concentrations of 15 to 20 mg/L associated with increased attainment of an AUC/MIC≥ 400 in patients with presumed MRSA infection? CM Hale, RW Seabury, JM Steele, W Darko, CD Miller Journal of pharmacy practice 30 (3), 329-335, 2017 | 62 | 2017 |
| Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor–, protease inhibitor–, and raltegravir … N Patel, S Abdelsayed, M Veve, CD Miller Annals of Pharmacotherapy 45 (3), 317-324, 2011 | 58 | 2011 |
| Impact of a pharmacist-driven beta-lactam allergy interview on inpatient antimicrobial therapy: a pilot project NS Sigona, JM Steele, CD Miller Journal of the American Pharmacists Association 56 (6), 665-669, 2016 | 49 | 2016 |
| Rilpivirine: a new addition to the anti-HIV-1 armamentarium. CD Miller, J Crain, B Tran, N Patel Drugs of Today (Barcelona, Spain: 1998) 47 (1), 5-15, 2011 | 39 | 2011 |
| Retrospective assessment of desmopressin effectiveness and safety in patients with antiplatelet-associated intracranial hemorrhage EA Feldman, G Meola, S Zyck, CD Miller, S Krishnamurthy, GM Cwikla, ... Critical care medicine 47 (12), 1759-1765, 2019 | 35 | 2019 |
| Characterization of drug-related problems occurring in patients receiving outpatient antimicrobial therapy CM Hale, JM Steele, RW Seabury, CD Miller Journal of pharmacy practice 30 (6), 600-605, 2017 | 29 | 2017 |
| The Impact of AUC-Based Monitoring on Pharmacist-Directed Vancomycin Dose Adjustments in Complicated Methicillin-Resistant Staphylococcus aureus Infection AM Stoessel, CM Hale, RW Seabury, CD Miller, JM Steele Journal of pharmacy practice 32 (4), 442-446, 2019 | 25 | 2019 |
| In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis WD Kufel, AP Eranki, KM Paolino, A Call, CD Miller, BT Mogle Journal of Antimicrobial Chemotherapy 74 (7), 2117-2118, 2019 | 21 | 2019 |
| A cross-sectional study comparing the frequency of drug interactions after adding simeprevir-or sofosbuvir-containing therapy to medication profiles of hepatitis C monoinfected … N Patel, M Nasiri, A Koroglu, S Bliss, M Davis, LA McNutt, C Miller Infectious diseases and therapy 4, 67-78, 2015 | 20 | 2015 |
| Frequency of electrocardiogram testing among HIV‐infected patients at risk for medication‐induced QTc prolongation N Patel, M Veve, S Kwon, LA McNutt, D Fish, CD Miller HIV medicine 14 (8), 463-471, 2013 | 20 | 2013 |
| Prevalence of drug–drug interactions upon addition of simeprevir-or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection N Patel, M Nasiri, A Koroglu, R Amin, L McGuey, LA McNutt, M Roman, ... AIDS Research and Human Retroviruses 31 (2), 189-197, 2015 | 18 | 2015 |
| Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: a single-center … KA Parsels, RW Seabury, S Zyck, CD Miller, S Krishnamurthy, W Darko, ... The American Journal of Emergency Medicine 55, 16-19, 2022 | 17 | 2022 |
| Y-site incompatibility between premix concentrations of vancomycin and piperacillin-tazobactam: do current compatibility testing methodologies tell the whole story? WD Kufel, CD Miller, PR Johnson, K Reid, JJ Zahra, RW Seabury Hospital Pharmacy 52 (2), 132-137, 2017 | 17 | 2017 |
| Nephrotoxicity risk and clinical effectiveness of continuous versus intermittent infusion vancomycin among patients in an outpatient parenteral antimicrobial therapy program P Shakeraneh, T Fazili, D Wang, T Gilotra, JM Steele, RW Seabury, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (4 …, 2020 | 16 | 2020 |
